Last updated on May 2019

Safety and Effectiveness of TactiCath Contact Force Sensor Enabled (TactiCath SE) Catheter for Ablation of Drug Refractory Symptomatic Persistent Atrial Fibrillation

Brief description of study

This clinical investigation is intended to demonstrate the safety and effectiveness of the TactiCath Contact Force Ablation Catheter, Sensor Enabled (TactiCath SE) for use in cardiac electrophysiological mapping and for the treatment of drug-refractory, recurrent symptomatic persistent atrial fibrillation (AF) when used in conjunction with a compatible radiofrequency (RF) generator and three-dimensional mapping system. This clinical investigation will be conducted under an investigational device exemption (IDE) and is intended to support market approval of the TactiCath SE ablation catheter for the treatment of drug refractory, symptomatic persistent atrial fibrillation in the United States.

Clinical Study Identifier: NCT03650556

Find a site near you

Start Over

Jersey Shore University Medical Center

Neptune, NJ United States
  Connect »